162 related articles for article (PubMed ID: 26727829)
1. COMPLETE CORRECTION OF ANEMIA WITH RECORMON® (ERYTHROPOIETIN β) IN PATIENTS ON CHRONIC HEMODIALYSIS.
Dimković N; Mitić I; Andrić B; Lilić Havidža B; Jelačić R; Milić N
Med Pregl; 2015; 68(9-10):324-30. PubMed ID: 26727829
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
4. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
[TBL] [Abstract][Full Text] [Related]
5. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
7. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
8. Epoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure.
Tilkian EE; Tzekov VD; Pandeva SM; Kumchev EP; Nikolov DG; Dimitrakov JD; Dimitrakov DD
Folia Med (Plovdiv); 2000; 42(3):11-5. PubMed ID: 11347329
[TBL] [Abstract][Full Text] [Related]
9. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
10. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
Biggar P; Ketteler M; Hennemann H; Dömling R
Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
[TBL] [Abstract][Full Text] [Related]
11. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
12. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study.
Pascual J; Teruel JL; Moya JL; Liaño F; Jiménez-Mena M; Ortuño J
Clin Nephrol; 1991 Jun; 35(6):280-7. PubMed ID: 1831414
[TBL] [Abstract][Full Text] [Related]
13. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.
Foley RN; Parfrey PS; Morgan J; Barré PE; Campbell P; Cartier P; Coyle D; Fine A; Handa P; Kingma I; Lau CY; Levin A; Mendelssohn D; Muirhead N; Murphy B; Plante RK; Posen G; Wells GA
Kidney Int; 2000 Sep; 58(3):1325-35. PubMed ID: 10972697
[TBL] [Abstract][Full Text] [Related]
14. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
[TBL] [Abstract][Full Text] [Related]
15. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
16. Worsening of left ventricular diastolic function during long-term correction of anemia with erythropoietin in chronic hemodialysis patients--an assessment by radionuclide ventriculography at rest and exercise.
Topuzović N
Int J Card Imaging; 1999 Jun; 15(3):233-9. PubMed ID: 10472525
[TBL] [Abstract][Full Text] [Related]
17. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
Silberberg J; Racine N; Barre P; Sniderman AD
Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
[TBL] [Abstract][Full Text] [Related]
18. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
Tarng DC; Huang TP; Doong TI
Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
Fishbane S; Berns JS
Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
[TBL] [Abstract][Full Text] [Related]
20. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
